Found this while googling Dr Jakob Dupont:
Prior to his role at Gossamer Bio, he served as Vice President and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin®, Perjeta®, Kadcyla®, and Tecentriq®, among others. Prior to that, Dr. Dupont was Chief Medical Officer and Senior Vice President of OncoMed Pharmaceuticals, Inc., where he oversaw the successful submissions of eight investigational new drug applications (INDs) and 26 clinical trial initiations.
https://www.bio.org/events/bio-investor-forum/speakers/1246770
Found this while googling Dr Jakob Dupont:Prior to his role at...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.003(5.26%) |
Mkt cap ! $395.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.7¢ | 5.4¢ | $1.444M | 26.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 3824179 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 172983 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |